May 26, 2020

Factor Bioscience Granted U.S. Patent for mRNA Vectorization of TALENs Technology

– Patented methods form the foundation of clinical-stage allogeneic CAR T-cell therapies

– Other applications include allogeneic stem cell-derived therapies and therapeutic gene editing for the treatment of genetic diseases

– Additional patents pending in the U.S. and in other countries

CAMBRIDGE, Mass., May 26, 2020 /PRNewswire/ — Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing therapeutic cell-engineering technologies, today announced that the United States Patent and Trademark Office has granted Factor Bioscience U.S. Patent No. 10,662,410 covering methods for producing a gene-edited cell using mRNA encoding transcription activator-like effector nucleases (TALENs).

The technology covered by this patent has wide-ranging applications in the development of engineered cell therapies and is already being used in the most advanced allogeneic CAR T-cell therapies, which are currently undergoing clinical testing. In these therapies, the patented methods are used to inactivate the endogenous T-cell receptor to prevent therapeutic T cells from causing graft-versus-host-disease (GvHD), and to perform other key cell-engineering steps.